Equity · Healthcare
Summit Therapeutics Inc. (SMMT) perpetual futures
Summit Therapeutics Inc. is a biopharmaceutical firm developing treatments for infectious diseases, focusing on Clostridioides difficile infection and multidrug-resistant bacteria.
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:SMMT
Loads TradingView's third-party widget (about 1 MB) on demand.
Trading data
Perpetual market activity
0/1 live markets
Trading data
Perpetual market activity
Spot performance
Best venues for this underlying
Best liquidity
-Tightest spread
-Highest volume
-Next catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $33.13 |
| 12-month target range (low – high) | $20 – $41 |
| Ratings in the provider's consensus | 23 |
Price targets as of 2026-11-22
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 1 | 10 | 6 | 0 | 1 |
| Oct 2026 | 1 | 10 | 6 | 0 | 0 |
| Sep 2026 | 1 | 10 | 7 | 0 | 0 |
| Aug 2026 | 1 | 9 | 7 | 0 | 2 |
| Jul 2026 | 1 | 9 | 5 | 0 | 2 |
| Jun 2026 | 1 | 9 | 5 | 0 | 2 |
| May 2026 | 1 | 11 | 5 | 0 | 2 |
| Apr 2026 | 1 | 11 | 4 | 0 | 1 |
| Mar 2026 | 1 | 11 | 4 | 0 | 1 |
| Feb 2026 | 1 | 11 | 3 | 0 | 1 |
| Jan 2026 | 1 | 11 | 3 | 0 | 1 |
| Dec 2025 | 1 | 11 | 3 | 0 | 2 |
Ownership
Institutional · 2026-Q3Reference market activity
SMMT-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25Director and Co-CEO Robert W. Duggan exercised stock options into 300,000 common shares at a $1.06 exercise price, leaving 831,000 shares owned after.
Director and Co-CEO Mahkam Zanganeh exercised 300,000 stock options at $1.06 each, converting them into 300,000 common shares. He held 831,000 common shares and 500,000 remaining options after the transaction.
Summit Therapeutics director and Co-CEO Robert W. Duggan exercised options on 500,000 common shares at $1.06 each on 2026-11-16, per SEC Form 4. He held 531,000 shares afterward.
Director and Co-CEO Mahkam Zanganeh exercised 500,000 stock options at $1.06 each, converting them into 500,000 common shares, leaving 531,000 common shares owned.
COO and CFO Soni Manmeet Singh exercised options on 100,000 shares at $1.37, converting stock options into common stock; he held 3,224,375 common shares afterward.
Summit Therapeutics officer Anand Bhaskar (Chief Accounting Officer) received a grant (A-Award) of 100,000 common shares at $0.00 on 2026-10-08, bringing holdings to 261,047 shares. Form 4 filed 2026-10-14. A grant is not an open-market purchase.
Co-CEO Mahkam Zanganeh purchased 3,810,000 shares of Summit Therapeutics common stock on the open market at $13.12 per share, bringing total ownership to 573,883,879 shares.
Robert W. Duggan (Co-CEO, director, 10% owner) purchased 3,810,000 shares of common stock on the open market at $13.12 per share, bringing his total ownership to 573,883,879 shares.
Robert W. Duggan, Co-CEO and director of Summit Therapeutics, purchased 100,000 shares of common stock on the open market at $14.60 per share, bringing his total ownership to 25,824,474 shares.
Co-CEO Mahkam Zanganeh purchased 100,000 shares of common stock on the open market at $14.60 per share, bringing total ownership to 25,824,474 shares.
COO/CFO Manmeet Singh Soni bought 50,000 shares of Summit Therapeutics on the open market across two trades at $14.43-$14.46, now owning 3,098,603 shares.
Summit Therapeutics CAO Anand Bhaskar was granted a stock option to buy 30,000 shares at an $18.83 exercise price, holding 30,000 options after.
Summit Therapeutics Co-CEO Mahkam Zanganeh was granted 11,232 stock options (exercise price $17.52) on 2026-01-02, a compensation award rather than an open-market purchase. Following this grant, she held 11,232 options.
Co-CEO Robert W. Duggan was granted 11,232 stock options with a $17.52 exercise price, as compensation.
Director Robert F. Booth was granted stock options for 42,180 shares total (two awards) with a $17.52 exercise price, as compensation - not an open-market purchase.
Director Xia Yu was awarded a stock option for 35,000 shares of Summit Therapeutics at an exercise price of $17.52, bringing total holdings to 35,000 shares.
Director Jeff Huber was granted stock options to buy 44,885 shares of Summit Therapeutics at a $17.52 exercise price, across two award transactions.
Filings
55 · Latest SEC filingsDirector and Co-CEO Robert W. Duggan exercised stock options into 300,000 common shares at a $1.06 exercise price, leaving 831,000 shares owned after.
Director and Co-CEO Mahkam Zanganeh exercised 300,000 stock options at $1.06 each, converting them into 300,000 common shares. He held 831,000 common shares and 500,000 remaining options after the transaction.
Director and Co-CEO Mahkam Zanganeh exercised 500,000 stock options at $1.06 each, converting them into 500,000 common shares, leaving 531,000 common shares owned.
COO and CFO Soni Manmeet Singh exercised options on 100,000 shares at $1.37, converting stock options into common stock; he held 3,224,375 common shares afterward.
Summit Therapeutics director and Co-CEO Robert W. Duggan exercised options on 500,000 common shares at $1.06 each on 2026-11-16, per SEC Form 4. He held 531,000 shares afterward.
Summit Therapeutics officer Anand Bhaskar (Chief Accounting Officer) received a grant (A-Award) of 100,000 common shares at $0.00 on 2026-10-08, bringing holdings to 261,047 shares. Form 4 filed 2026-10-14. A grant is not an open-market purchase.
Co-CEO Mahkam Zanganeh purchased 3,810,000 shares of Summit Therapeutics common stock on the open market at $13.12 per share, bringing total ownership to 573,883,879 shares.
Robert W. Duggan (Co-CEO, director, 10% owner) purchased 3,810,000 shares of common stock on the open market at $13.12 per share, bringing his total ownership to 573,883,879 shares.
Robert W. Duggan, Co-CEO and director of Summit Therapeutics, purchased 100,000 shares of common stock on the open market at $14.60 per share, bringing his total ownership to 25,824,474 shares.
COO/CFO Manmeet Singh Soni bought 50,000 shares of Summit Therapeutics on the open market across two trades at $14.43-$14.46, now owning 3,098,603 shares.
Co-CEO Mahkam Zanganeh purchased 100,000 shares of common stock on the open market at $14.60 per share, bringing total ownership to 25,824,474 shares.
Summit Therapeutics CAO Anand Bhaskar was granted a stock option to buy 30,000 shares at an $18.83 exercise price, holding 30,000 options after.
Director Robert F. Booth was granted stock options for 42,180 shares total (two awards) with a $17.52 exercise price, as compensation - not an open-market purchase.
Director Mostafa Ronaghi was granted stock options to buy 35,000 shares of Summit Therapeutics at $17.52 per share, holding 35,000 options after the grant.
Kenneth A. Clark, a director of Summit Therapeutics, was granted stock options for 52,796 shares (2 awards) with an exercise price of $17.52. This was a compensation grant, not an open-market purchase.
Co-CEO Robert W. Duggan was granted 11,232 stock options with a $17.52 exercise price, as compensation.
Director Xia Yu was awarded a stock option for 35,000 shares of Summit Therapeutics at an exercise price of $17.52, bringing total holdings to 35,000 shares.
Director Jeff Huber was granted stock options to buy 44,885 shares of Summit Therapeutics at a $17.52 exercise price, across two award transactions.
Summit Therapeutics Co-CEO Mahkam Zanganeh was granted 11,232 stock options (exercise price $17.52) on 2026-01-02, a compensation award rather than an open-market purchase. Following this grant, she held 11,232 options.
Transcripts
Earnings callsFY2025 Q42026-02-23
Earnings calls
AI summary
positiveSummit announced completion of screening for the HARMONi-3 squamous non-small cell lung cancer cohort and amended the statistical plan to include an interim PFS analysis in Q2 2026. The company reported a strong cash position of $713.4 million with no debt, and ivonescimab continues to generate positive clinical data with 4 Phase III trials read out to date, all positive. New Phase III studies were announced including the ILLUMINE trial in head and neck cancer and collaborations with Revolution Medicines and GSK.
Key takeaways
- HARMONi-3 squamous cohort enrollment completed ahead of schedule with interim PFS analysis planned for Q2 2026; final PFS and interim OS data expected in H2 2026
- FDA accepted BLA filing for ivonescimab in EGFR mutant NSCLC with PDUFA target date of November 14, 2026; commercial capabilities ramping up for potential launch
- Four Phase III trials with ivonescimab have read out to date with all positive results; 15 total Phase III trials announced across multiple tumor types
- New Phase III ILLUMINE study in head and neck cancer sponsored by GORTEC cooperative group enrolling ~780 patients; evaluating ivonescimab monotherapy and combination with ligufalimab versus pembrolizumab
- Clinical collaborations initiated: first patient dosed in Revolution Medicines trial combining ivonescimab with RAS inhibitors; GSK B7-H3 ADC combination study expected to begin mid-2026
Financial highlights
- Cash position: $713.4 million at end of 2025 with no debt
- Q4 2025 GAAP operating expenses: $225 million vs $234.2 million in Q3 2025, driven by lower stock-based compensation ($19.1 million)
- Q4 2025 non-GAAP operating expenses: $113.3 million vs $103.4 million in Q3 2025, increase driven by R&D spend on HARMONi-3 and HARMONi-7 trials
- Full year 2025 G&A spend (excluding stock-based compensation): ~$43 million with quarterly run rate of $10-11 million
Guidance
- HARMONi-3 squamous cohort: interim PFS analysis planned for Q2 2026; final PFS and interim OS data expected in H2 2026
- HARMONi-3 non-squamous cohort: enrollment completion expected in H2 2026; final PFS data anticipated in H1 2027
- EGFR mutant NSCLC BLA: FDA PDUFA target action date of November 14, 2026
- ILLUMINE head and neck cancer Phase III: initial enrollment expected to begin early Q2 2026 with approximately 780 patients across Europe and China, with potential U.S. expansion
Q&A themes
- Interim PFS analysis decision driven by positive HARMONi-2 and HARMONi-6 data from Akeso studies, allowing earlier regulatory discussions while maintaining final PFS and interim OS timelines in H2 2026
- OS maturity and regulatory pathway: three of four Phase III trials show OS hazard ratios below 0.8 (clinically meaningful threshold); FDA clearly required OS data for BLA filing but company believes data package demonstrates favorable benefit-risk profile
- Commercial strategy: EGFR indication is smallest population; squamous cohort 2.5-3x larger; non-squamous approximately double squamous; significant synergies in same physician base and institutions with most G&A expense coming before PDUFA
- Head and neck cancer expansion driven by cooperative group initiative; regulatory considerations including Project Optimus and contribution of components addressed in 3-arm study design; Chinese Phase III also ongoing via Akeso
Risks
- Overall survival maturity at interim PFS analysis will be limited, requiring regulatory discussion on path forward; study not powered for OS at interim timepoint
- Regulatory approval uncertain despite positive PFS data; FDA has indicated OS benefit necessary for EGFR indication and approach to frontline lung cancer approvals based on PFS alone remains to be determined
- Commercial execution risk for EGFR mutant NSCLC launch in November 2026; company building sales infrastructure and manufacturing capacity while still awaiting regulatory decision
FY2025 Q32025-10-20
Earnings calls
AI summary
positiveHARMONi-6 met its primary endpoint with ivonescimab plus chemotherapy demonstrating a 0.60 hazard ratio for progression-free survival versus tislelizumab plus chemotherapy (11.14 vs 6.90 months, p<0.0001) in patients with advanced squamous NSCLC. Summit plans to submit a biologics license application in Q4 2025 based on these results, while also amending the HARMONi-3 global Phase III trial to separately analyze squamous and non-squamous cohorts and expanding into colorectal cancer with the HARMONi-GI3 Phase III study.
Key takeaways
- HARMONi-6 positive for primary endpoint: ivonescimab HR 0.60 (p<0.0001) vs tislelizumab; median PFS 11.14 vs 6.90 months
- Ivonescimab demonstrated benefit across all PD-L1 expression levels (HR: 0.55 negative, 0.63 low, 0.71 high) and key subgroups including patients with central tumors, vessel encasement, and hemoptysis history
- Safety profile comparable between arms with <2% Grade 3+ bleeding events and low discontinuation rates (3.4% vs 4.2%)
- BLA submission planned for Q4 2025; HARMONi-3 amended to separate squamous (600 patients, PFS readout H2 2026) and non-squamous (1,000 patients) cohorts with independent ITT analyses
- Expanding beyond lung: HARMONi-GI3 Phase III in first-line unresectable metastatic colorectal cancer initiating U.S. sites by end of 2025; 14 total planned/ongoing Phase III trials across multiple solid tumors
Financial highlights
- Q3 2025 cash position: $238.6 million
- Q3 2025 GAAP operating expenses: $234.2 million (vs $568.4 million Q2 2025, decrease due to prior quarter stock-based compensation)
- Q3 2025 non-GAAP operating expenses: $103.4 million (vs $89.6 million Q2 2025, increase due to R&D for HARMONi-3 and HARMONi-7)
- ATM facility available with approximately $350 million; management indicated inbound capital interest
Guidance
- HARMONi-3 squamous cohort: enrollment completion expected Q1 2026; PFS event readout expected H2 2026
- HARMONi-3 non-squamous cohort: enrollment completion expected H2 2026; PFS event readout expected Q1 2027
- HARMONi-GI3 colorectal Phase III: U.S. site activation planned by end of 2025; enrollment of ~600 patients
- Additional Phase III clinical studies to be announced in Q1 2026
Q&A themes
- HARMONi-6 OS data expected in 2026; timing driven by events rather than calendar
- PD-L1 negative patients showed larger differential benefit (HR 0.55), potentially reflecting importance of VEGF component, though all subgroups favored ivonescimab
- HARMONi-3 protocol amendments reduce regulatory risk via independent histology-specific ITT analyses and allow earlier squamous cohort readout
- Prior regulatory approvals (amivantamab, Dato) in EGFR-positive setting based on PFS without statistically significant OS support precedent for BLA
Risks
- FDA stated OS benefit is necessary for marketing authorization; HARMONi study shows PFS benefit but OS data immature at time of planned BLA submission
- Expansion to multiple Phase III trials (14 total) and new indication (colorectal) increases execution risk and capital requirements
- China-derived data translatability to U.S. market and HARMONi-6 single-region design may face regulatory scrutiny despite historical precedent
FY2025 Q12025-05-01
Earnings calls
AI summary
positivePartner Akeso achieved NMPA approval for ivonescimab as first-line monotherapy in PD-L1 positive NSCLC and reported positive overall survival trends (HR 0.777 at 39% maturity) from HARMONi-2. HARMONi-6 met its primary endpoint showing statistically significant PFS benefit with chemotherapy. Summit expects top-line data from its global Phase III HARMONi trial in mid-2025.
Key takeaways
- Akeso received NMPA approval for ivonescimab as frontline monotherapy in PD-L1 positive NSCLC based on HARMONi-2 PFS data
- HARMONi-2 interim OS analysis showed clinically meaningful trend (HR 0.777) at 39% data maturity with minimal alpha allocation
- HARMONi-6 met primary endpoint with statistically significant PFS improvement for ivonescimab plus chemotherapy versus PD-1 inhibitor plus chemotherapy in squamous NSCLC
- Summit expects HARMONi global Phase III top-line data in mid-2025 with both PFS and OS endpoints
- Over 2,300 patients treated with ivonescimab; 11 Phase III trials announced, ongoing or completed; 5 Phase III trials currently ongoing
Financial highlights
- Q1 2025 cash position: $361 million (debt-free after Q4 2024 debt payoff)
- Q1 2025 GAAP R&D expenses: $51.2 million (flat vs Q4 2024); non-GAAP R&D: $47.1 million
- Q1 2025 GAAP G&A expenses: $15.6 million vs $14.2 million Q4 2024; non-GAAP G&A: $8.6 million
- Q1 2025 non-GAAP operating expenses: $55.7 million vs $54.6 million Q4 2024
Guidance
- HARMONi global Phase III top-line data expected mid-2025 with both PFS and OS primary endpoints
- HARMONi-6 full data set planned for presentation at major medical conference later in 2025
- Additional clinical development plan details and expansion beyond lung cancer expected later in 2025
- Pfizer ADC combination trials expected to initiate later in 2025
Q&A themes
- HARMONi EGFR trial bar for success focuses on data consistency with China data; no specific numerical threshold prescribed; safety profile expected to match China data
- Geographic data breakdown for HARMONi will include China vs ex-China (North America, Europe) with forest plots likely presented at medical conferences
- OS statistical significance not required for HARMONi BLA filing; precedent shows other regimens in this setting have not shown statistically significant OS benefit
- HARMONi-3 and HARMONi-7 will provide approximately equal enrollment of squamous and non-squamous patients; statistical plan not yet publicly detailed
Risks
- HARMONi-2 OS data at early interim (39% maturity) with minimal alpha allocation; hazard ratio could move unfavorably with longer follow-up
- Overall survival not historically demonstrated in second-line EGFR-mutant NSCLC setting, creating uncertainty for HARMONi trial outcome
FY2024 Q42025-02-24
Earnings calls
AI summary
positiveSummit Therapeutics reported strong clinical progress on its lead candidate Ivonescimab, with HARMONi (second-line EGFR-mutant NSCLC) enrollment completed and top-line data expected mid-2025 including both PFS and OS endpoints. The company announced a clinical trial collaboration with Pfizer to evaluate Ivonescimab combined with multiple Pfizer ADCs across solid tumors starting mid-2025. Summit ended 2024 with $412 million in cash, zero debt, and expanded its first-line NSCLC development program (HARMONi-3, HARMONi-7) with ongoing global site activations.
Key takeaways
- HARMONi (second-line EGFR-mutant NSCLC) completed enrollment in Q4 2024 with top-line data including PFS and OS expected mid-2025
- New Pfizer clinical collaboration to evaluate Ivonescimab plus multiple vedotin-based ADCs in multiple solid tumor types, with trials expected to initiate mid-2025; Pfizer responsible for trial operations and costs
- HARMONi-3 (first-line metastatic NSCLC) amended to include non-squamous histology, expanding addressable population 2-3x; non-squamous enrollment recently began in US with other regions planned for Q2 2025
- HARMONi-7 (first-line metastatic NSCLC, PD-L1 high) ahead of schedule with US site activation underway and other regions planned for Q2 2025
- Over 2,300 patients treated with Ivonescimab across clinical trials; 14 publications across 7 tumor types and 5 oral presentations at major conferences in 2024
Financial highlights
- Cash position: $412 million at end of 2024, debt-free
- GAAP R&D expenses FY2024: $150.8 million vs. $59.4 million in 2023; non-GAAP R&D: $134.8 million vs. $55 million in 2023
- Acquired in-process R&D FY2024: $15 million (related to Akeso licensing agreement amendment for LATAM/MENA/Africa) vs. $520.9 million in 2023
- Non-GAAP operating expenses FY2024: $175.3 million vs. $596.5 million in 2023
Guidance
- HARMONi top-line data expected mid-2025 with both PFS and OS primary endpoints
- Pfizer ADC combination trials expected to initiate mid-2025
- HARMONi-3 non-squamous site activation in other regions (Europe and beyond) expected Q2 2025
- HARMONi-7 site activation in other regions expected Q2 2025; expect near 100% of sites activated by end of 2025 for both first-line trials
Q&A themes
- HARMONi-2 OS timing: Akeso partners expected to reach interim analysis event numbers by end of 2025; no additional information disclosed by Summit
- HARMONi regulatory pathway: PFS alone may be adequate for approval based on precedent, though OS statistical significance would be preferred; regulatory discussions ongoing regarding data presentation for regional differences
- HARMONi-3 enrollment: Too early to provide timeline until all sites activated across territories; will provide clarity after one to two quarters of run rate data
- Pfizer collaboration specifics: Phase 1b/2 trials expected, multiple ADC types being explored, multiple solid tumor settings beyond lung cancer, additional details to follow as trials approach launch
Risks
- HARMONi data dependent on achieving statistical significance for regulatory approval pathways; OS data achievement timeline uncertain
- HARMONi-3 enrollment timeline uncertain pending activation of sites in Europe and other regions; expansion to non-squamous patients adds operational complexity
- Pfizer ADC combinations require safety evaluation; potential overlapping toxicities with VEGF inhibition and various ADC payloads to be characterized in Phase 1b/2 studies
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.Company data
Company intelligence
Updated: Nov 22, 2026, 10:39 AM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Robert W. Duggan
- Employees
- 265
- IPO date
- Mar 5, 2015
- Country
- US
- Exchange
- NASDAQ Global Market
Rating factors
- Return on equityi
- 1/5
- Return on assetsi
- 1/5
- Debt to equityi
- 4/5
- Price to earningsi
- 1/5
- Price to booki
- 1/5
Company press releases
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| XBI | 1.27% | 7.6M |
| VTI | 0% | 3.7M |
| VB | 0.02% | 2.7M |
| FDGRX | 0.04% | 2M |
| VXF | 0.03% | 1.8M |
| VBR | 0.03% | 1.7M |
| IBB | 0.17% | 1M |
| FBIOX | 0.24% | 803.5K |
| NIW | 0.06% | 773.3K |
| IWP | 0.07% | 769.7K |
| BTEC.L | 0.96% | 629.6K |
| FSPHX | 0.17% | 602.1K |
Analyst track record
How the analysts covering SMMT have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 121 | 261 |
| Analysts | 20 | 27 |
| Buy / hold / sell | 70 / 48 / 3 | 194 / 53 / 14 |
| Upgrades / downgrades / initiations | 3 / 3 / 1 | 4 / 4 / 19 |
| Price targets hit / missed | 3 / 93 (3%) | 8 / 192 (4%) |
| Avg. return after a rating (TipRanks) | -56.4% | -57.4% |
| Best / worst call | +27.4% / -92.0% | +51.0% / -92.0% |
After buy calls on this stock: median 21-day move -1.2% vs S&P 500 -2.0% (n = 182)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Bradley CaninoGuggenheim55% hit rate on this stock · 11 targets measuredBuytarget $38.00Jul 23, 2026
- Yigal NochomovitzCiti42% hit rate on this stock · 12 targets measuredBuytarget $42.00Nov 16, 2026
- Cory KasimovEvercore ISI25% hit rate on this stock · 8 targets measuredBuytarget $34.00Nov 5, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 18, 2026 | Daina GrayboschLeerink PartnersNov 18, 2026 | HoldMaintained | –↗ | article ↗ |
| Nov 18, 2026 | Jeffrey WalchBernsteinNov 18, 2026 | SellDowngraded | $8.30↗ | article ↗ |
| Nov 16, 2026 | Dara AzarStifel NicolausNov 16, 2026 | BuyMaintained | $37.00↗ | article ↗ |
| Nov 16, 2026 | Kelsey GoodwinPiper SandlerNov 16, 2026 | HoldMaintained | $16.00↗ | article ↗ |
| Nov 16, 2026 | Mitchell KapoorH.C. WainwrightNov 16, 2026 | HoldReiterated | –↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 121 ratings
BingX